TYPE 2 INFLUENCE TIAZOLIDINEDION ON GLICOREGULATION IN PATIENTS WITH DIABETES MELLITUS

S. Pajović ,
S. Pajović

Internal Clinic, Faculty of Medicine, University of Priština - Kosovska Mitrovica , Mitrovica , Kosovo

A. Jovanović ,
A. Jovanović

Internal Clinic, Faculty of Medicine, University of Priština - Kosovska Mitrovica , Mitrovica , Kosovo

T. Novaković ,
T. Novaković

Internal Clinic, Faculty of Medicine, University of Priština - Kosovska Mitrovica , Mitrovica , Kosovo

V. Perić ,
V. Perić

Internal Clinic, Faculty of Medicine, University of Priština - Kosovska Mitrovica , Mitrovica , Kosovo

S. Sovtić ,
S. Sovtić

Internal Clinic, Faculty of Medicine, University of Priština - Kosovska Mitrovica , Mitrovica , Kosovo

R. Stolić
R. Stolić

Internal Clinic, Faculty of Medicine, University of Priština - Kosovska Mitrovica , Mitrovica , Kosovo

Published: 01.12.2007.

Volume 35, Issue 2 (2007)

pp. 29-31;

https://doi.org/10.70949/pramed200702197P

Abstract

Diabetes mellitus with one`s chronical complications is the cause of the large percent morbidites and mortality, among the population. With regard to a lot of people who have diabetes mellitus tip 2 (WHO-over 170.000.000 peoples), adequate therapy is very important. By this stady, we wont to show positive consequence new therapy for medication diabetes mellitus typ 2, chiefly application tiazolidinedion in therapy. Handlend 25 patientis with diabetes mellitus typ 2 during 3-mounth observed. Patients were divide in II groups forms on basic of the kind therapy. At the end of 3-mounth, derived results (decrease HbA1c from 7.9%±1.24% to 6.99±0.89%; data value fasting glycemia from 8.99mmol/l±2.08 mmol/l to 7.45±1.35 mmol/l, and value glycemia after meal 10.36 mmol/l±2.18 mmol/l to 8.18 mmol/l±1.31 mmol/l) indicate validity the introduction tiazolidinedion in therapy diabetes mellitus type 2.

Keywords

References

1.
Nolan JJ, Jones NP, Patwardhan R, Deacon LF. Rosiglitazone taken once daily provides effective glycemic control in patients with type 2 diabetes mellitus. Diabetologia. 17:287–94.
2.
Raskin P, Rappaport EB, Colc ST, Yan Y, Patwardhan R, Freed MI. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type 2 diabetes. Diabetologia. 43:278–84.
3.
Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 45:1661–9.
4.
Glazli MN, Perez JE, Antonucci TK, Driscoll OH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in IDDM. The Troglitazone Study Group Diabetes. 46:433–9.
5.
Forman LM, Simmons DA, Diamond RH. Hepatic failure in patients taking rosiglitazone. Annals of Internal Medicine. 132:118–21.
6.
Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. The Troglitazone and Exogenous Insulin Study Group New England Journal of Medicine. 338:861–6.
7.
Al-Salman J, Arjamand H, Kemp DG, Mitzal M. Hepatocellular injury in patients receiving rosiglitazone: A case report. Annals of Internal Medicine. 132:121–4.
8.
Riddle M. Combining sulfonylureas and other oral agents. American Journal of Medicine. 108(Suppl 6a):15–22.
9.
Ovalle F, Bell DSH. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocrine Practice. 4:146–7.
10.
Buse J. Combining insulin and oral agents. American Journal of Medicine. 108(Suppl 6a):28–32.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by